Mitigate


The Mitigate Project

Agents: A novel PET-CT tracer specifically developed to target cell surface receptors of GIST cells
Phase I/IIa
Status  Open, recruiting
Sponsor Medical University Innsbruck, European Union

Further information: www.mitigate-project.eu

WHO is the trial for?

 
  • Patients with progressive disease who have at least been treated with imatinib are eligible
  • The study addresses patients with oligometastatic GIST disease predominantly localised in the liver
  • Information required: Mutation analysis of the tumour and current cross sectional imaging (not older than 4 weeks) that documents disease progression according to RECIST

WHAT is the key question that this trial is attempting to answer?

The project tries to answer the question whether the use of a novel PET-CT tracer specifically developed to target cell surface receptors of GIST cells leads to benefits from the imaging procedure, such as improved tumour volume definition and better detection of disease.

WHY patients might want to participate?

 
  • Since the first step of the trial is diagnostic rather than therapeutic, patients may derive benefits from the imaging procedure, such as improved tumour volume definition and better detection of disease.
  • Patients will receive preliminary information about the results within a short time (1 day) after the examination. The treating physician in conjunction with the study team will provide detailed results.


WHEN will the trial be open?

 The study is open (recruiting)


WHERE is the trial available?

 Medical University Innsbruck

STUDY DESIGN: What does the study look like?

 
  • Eligible patients with metastatic and progressing GIST will receive a PET CT examination with a new PET-CT tracer.
  • An improved tumour volume definition and lesion (metastasis) detection rate is expected. If the treating oncologist in conjunction with these diagnostic results determines that a minimally invasive treatment is advisable for the patient, then the MITIGATE partners at the University Medical Centre Mannheim (UHEI) and the Medical University of Innsbruck (MUI) may administer such therapeutic measures.

HOW do I get more information?

More information will be available on the MITIGATE homepage www.mitigate-project.eu.

CONNECT with other patients on this trial

If you want to connect to other patients on the trial, please contact the Mitigate team on This email address is being protected from spambots. You need JavaScript enabled to view it. and they will pass on your request and ask them to get in contact with you.

SHARE your experience

You want to share your experience on this trial?
Send us an e-mail to: This email address is being protected from spambots. You need JavaScript enabled to view it.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS of the study

Currently, there are no results yet. It is estimated that results will be available on the MITIGATE homepage end of 2017 (end of the project)

 

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken